Objective-A disintegrin and metalloproteinase ADAM17 (tumor necrosis factor-α [TNF]-converting enzyme) regulates soluble TNF levels. We tested the hypothesis that aging-induced activation in adipose tissue (AT)-expressed ADAM17 contributes to the development of remote coronary microvascular dysfunction in obesity. Approach and Results-Coronary arterioles (CAs, ≈90 µm) from right atrial appendages and mediastinal AT were examined in patients (aged: 69±11 years, BMI: 30.2±5.6 kg/m 2 ) who underwent open heart surgery. CA and AT were also studied in 6-month and 24-month lean and obese mice fed a normal or high-fat diet. We found that obesity elicited impaired endotheliumdependent CA dilations only in older patients and in aged high-fat diet mice. Transplantation of AT from aged obese, but not from young or aged, mice increased serum cytokine levels, including TNF, and impaired CA dilation in the young recipient mice. In patients and mice, obesity was accompanied by age-related activation of ADAM17, which was attributed to vascular endothelium-expressed ADAM17. Excess, ADAM17-shed TNF from AT arteries in older obese patients was sufficient to impair CA dilation in a bioassay in which the AT artery was serially connected to a CA. Moreover, we found that the increased activity of endothelial ADAM17 is mediated by a diminished inhibitory interaction with caveolin-1, owing to agerelated decline in caveolin-1 expression in obese patients and mice or to genetic deletion of caveolin-1. Conclusions-The present study indicates that aging and obesity cooperatively reduce caveolin-1 expression and increase vascular endothelial ADAM17 activity and soluble TNF release in AT, which may contribute to the development of remote coronary microvascular dysfunction in older obese patients. Visual Overview-An online visual overview is available for this article. well-established role in the development of insulin resistance in type 2 diabetes mellitus. 15, 16 In animal models of obesityassociated metabolic syndrome, increased plasma TNF was shown to be associated with coronary artery vasodilator dysfunction because of TNF-mediated increases in reactive oxygen species production and impaired endothelial nitric oxide (NO) synthase function. 17, 18 We recently provided evidence that increased reactive oxygen species and peroxynitrite formation impairs NO-mediated coronary arteriole dilation in patients with type 2 diabetes mellitus. 19 Previous clinical studies have revealed that elevated plasma and AT TNF levels strongly correlate with the severity of coronary artery disease in elderly. 12, [20] [21] [22] In this context, we 23 and others 24 have found that aging exacerbates obesity-associated vascular dysfunction in mouse models and that AT-derived cytokines, including TNF, play a pivotal role in the vascular impairment. Although these aforementioned studies provide evidence for a pathological role of AT-derived TNF in age-related vascular dysfunction, the underlying mechanisms of increased TNF production and its causative relationship with CMD remain largely unknown.
D
ysfunction of coronary resistance arteries develops in older patients, often in the absence of occlusive atherosclerotic lesions in the large coronary artery, which contributes to poor myocardial perfusion. 1 Cardiovascular complications arising specifically from coronary microvascular dysfunction (CMD) are less defined 2 and often viewed as an inevitable consequence of aging. CMD has recently emerged as the primary underlying pathology of a subset of cardiovascular diseases, such as heart failure with preserved ejection fraction (HFpEF). 3 HFpEF is increasingly prevalent in older patients, including both men and women, who often experience several comorbidities. 4 There is general agreement that HFpEF is uniquely driven by a chronic systemic inflammatory state, which selectively targets and adversely affects the coronary microcirculation. 5, 6 In 732 elderly Framingham study subjects, inflammatory mediators, such as tumor necrosis factor-α (TNF), interleukin-6, and C-reactive protein, were associated with increased risk for heart failure in people without previous myocardial infarction. 7 The nature of the underlying mechanisms of inflammatory mediator-induced CMD remains poorly understood. It is known that comorbid conditions, such as obesity, can dramatically accelerate the timeline to many cardiovascular complications and particularly so with advanced age. 8 Therefore, in this study, we sought to investigate the mechanisms by which proinflammatory changes in aged adipose tissue (AT) contribute to the development of CMD in older obese patients with cardiovascular diseases.
It has been long recognized that expansion of visceral AT (abdominal and intrathoracal) adversely affects metabolic homeostasis. 9 It is also known that pathological AT expansion is associated with excess production of adipokines 10, 11 and proinflammatory cytokines, including TNF. [12] [13] [14] TNF plays a well-established role in the development of insulin resistance in type 2 diabetes mellitus. 15, 16 In animal models of obesityassociated metabolic syndrome, increased plasma TNF was shown to be associated with coronary artery vasodilator dysfunction because of TNF-mediated increases in reactive oxygen species production and impaired endothelial nitric oxide (NO) synthase function. 17, 18 We recently provided evidence that increased reactive oxygen species and peroxynitrite formation impairs NO-mediated coronary arteriole dilation in patients with type 2 diabetes mellitus. 19 Previous clinical studies have revealed that elevated plasma and AT TNF levels strongly correlate with the severity of coronary artery disease in elderly. 12, [20] [21] [22] In this context, we 23 and others 24 have found that aging exacerbates obesity-associated vascular dysfunction in mouse models and that AT-derived cytokines, including TNF, play a pivotal role in the vascular impairment. Although these aforementioned studies provide evidence for a pathological role of AT-derived TNF in age-related vascular dysfunction, the underlying mechanisms of increased TNF production and its causative relationship with CMD remain largely unknown.
A disintegrin and metalloproteinase, ADAM17, also known as TNF-converting enzyme, regulates soluble TNF levels. 25 ADAM17 mRNA expression has been detected in mouse AT (both in visceral and in subcutaneous fat pads), which is readily upregulated after high fat feeding. 26 ADAM17 is sequestered and localized within cell membrane caveolae, where its activity is regulated through its interaction with caveolin-1 (Cav1), the main structural protein of membrane caveolae. [27] [28] [29] Our recent studies have shown that diabetic patients exhibit reactive oxygen species-dependent disruption of vascular endothelial caveolae 19 and that mice with genetic deletion of Cav1 develop coronary artery dilator dysfunction 19 and high blood pressure, when fed a high-fat diet (HFD). 30 The nature of mechanisms by which AT ADAM17 contributes to excess TNF release and the role of endothelial caveolae dysfunction in this process remain unknown in aging. These observations and considerations led us to hypothesize that aging of the AT is associated with transition to proinflammatory phenotype, which is characterized by ADAM17 activation and excess TNF production, thereby contributing to the development of CMD in older obese patients with cardiovascular diseases.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Reduced Dilation in Coronary Arterioles in Older Obese Patients
Coronary arteriole dilator function was examined in isolated coronary arterioles obtained from consecutive patients who underwent open heart surgery (Table) Figure 1A ). When examined by regression analyses, the age-related decline was found to be significant only in obese patients (BMI≥30 kg/m 2 ), whereas a nonsignificant negative trend was observed in the nonobese (BMI<30 kg/m 2 ; Figure 1C ). The age-related decline in bradykinin-induced coronary arteriole dilation was similar in men and women (r=−0.486 versus r=−0.629; P=0.131; Figure I in the onlineonly Data Supplement). In addition, no significant correlation was observed among age, obesity, and sodium nitroprusside (NO donor)-induced coronary arteriole dilation in this patient population ( Figure 1B and 1D ).
Reduced Coronary Artery Dilation Is Associated With Increased Serum Levels of Proinflammatory Cytokines in Aged Obese Mice
We examined mechanisms that could underlie obesity and aging-induced development of coronary artery dilator dysfunction in a mouse model of HFD-induced obesity. We assessed coronary artery dilations in young (6-month) and aged (24-month) obese mice fed a 3-month HFD, similar to the previously described. 24 Young and aged mice on a normal chow diet served as controls. Both young and aged mice had a similar weight gain after 3 months of HFD (gain in young: 10.7±2.6 g versus aged: 14.4±4.6 g, nonsignificant), although the final body weights were significantly higher in the aged HFD-fed mice (young: 29.4±2.6 g versus young HFD 45.1±2.6 g and aged: 39.4±5.2 g versus aged HFD 63.1±6.2 g; P<0.05). The active (spontaneously developed or preconstricted by U46619, 10 nmol/L, mean arteriolar tone: 38.8±9.9%) and passive (in the absence of extracellular Ca 2+ ) baseline diameters of isolated coronary arterioles were not significantly different in the 4 groups (diameters in µm, young, active: 97±6, passive: 133±4; young-HFD, active: 83±7, passive: 128±15; aged, active: 77±9, passive: 155±12; aged-HFD, active: 79±6, passive: 140±16). We found that coronary artery dilation in response to the endotheliumdependent agonist, acetylcholine, but not to sodium nitroprusside, was significantly reduced in the aged, with a further decline in aged HFD mice, when compared with young mice with normal or with an HFD (Figure 2A and 2B changes in the coronary artery dilator function were associated with significantly increased serum levels of cytokines, including TNF and interleukin-1β in the aged mice, and even a more prominent increase in TNF and interleukin-6 levels was observed in aged HFD mice, when compared with the young groups ( Figure 3 ).
AT Transplantation From Aged Obese Mice Increases TNF Levels and Impairs Coronary Artery Dilation in the Young Recipient
To test whether AT from the aged mice is a significant source of proinflammatory cytokines and whether it contributes to the development of coronary artery dilator dysfunction, we performed AT transplantation between aged and aged HFDfed mice to normal young recipient mice ( Figure 2C and 2D), similar to the previously described. 31 For controls, we transplanted AT from normal young mice into normal young recipients. To assure engrafting and connection with the host circulation, we injected rhodamine-dextran through the femoral vein of the recipient mice and detected the rhodamine dye in the vessel lumen within the transplanted fat pads ( Figure 2E ). Allografts showed no sign of necrosis ( Figure 2F , upper panels), but were infiltrated by polymorphonuclear leukocytes ( Figure 2F , lower panels) with a similar extent among the experimental groups as assessed by a semiquantitative histology analysis (14±4 versus 10±3 versus 14±3 polymorphonuclear leukocyte/field of observation, in young-to-young versus aged-to-young versus aged HFD-to-young allografts, respectively). Importantly, we found that after a 7-day AT transplantation from aged HFD, but not from aged, to young mice coronary artery dilation to acetylcholine became significantly reduced in the young recipients ( Figure 2G and 2H) . Among the inflammatory cytokines and chemokines we had found elevated in the aged HFD mice, TNF and MCP-1 (monocyte chemoattractant protein-1) levels were significantly increased in the serum of young recipients ( Figure 3B ). We also observed elevated interleukin-1β, CCL4 (chemokine [C-C motif] ligand 4), and CXCL10 (chemokine [C-X-C motif] ligand 10) serum levels after AT transplantation, but these cytokine levels were not increased in the aged HFD mice, and some of these changes may be attributed to transplantation procedures ( Figure 3B ).
Obesity and Aging Cooperatively Activates ADAM17 in Mouse and Human AT
Given the consistently and prominently elevated serum TNF levels in aged HFD-fed mice, as well as in young mice receiving AT transplants from the aged HFD mice, we next examined obesity and age-related changes in the expression and activity of the TNF-converting enzyme, ADAM17 in AT. Immunohistology analysis revealed that ADAM17 is abundantly expressed in adipocytes and even more prominently in blood vessels in the aged AT ( Figure 4A ). We found that ADAM17 protein expression (pro and matured forms; Figure 4B through 4D) was significantly increased in the AT of young HFD and aged HFD mice, when compared with controls. However, ADAM17 enzyme activity was found to be significantly increased only in the aged and aged HFD mice ( Figure 4E ). Two-way ANOVA revealed that the increased ADAM17 protein expression was related to HFD, but not to aging (HFD: P=0.021, aging: P=0.496, interaction: P=0.159), whereas increased ADAM17 enzyme activity was related to both HFD and aging (HFD: P=0.028, aging: P=0.002, interaction: P=0.919). Calcium channel blocker 24
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For continues variables, mean±SD are shown. ACEI/ARB indicates angiotensin-converting enzyme inhibitors/angiotensin receptor blockers; AMI, previous acute myocardial infarction; BMI, body mass index; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; EF, ejection fraction; HFrEF, heart failure with reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; n, number of patients studied; and SBP, systolic blood pressure.
We then examined age-related changes in ADAM17 expression and activity in AT in obese patients. We found no changes in adipocyte size in AT between younger and older obese patients (Figure 5A through 5C) with a similar BMI (BMI in younger: 32±3 versus older: 31±2 kg/m 2 , not significantly different), indicating a similar level of increased adiposity in this subset of patients. Similar to mice, we observed a prominent microvascular endothelial expression of ADAM17 in AT ( Figure 5D and 5E and Figure II in the online-only Data Supplement), which was also confirmed with immunoelectron microscopy ( Figure 5F through 5H). Importantly, we found a significant, age-related increase in ADAM17 enzyme activity in freshly dissected AT blood vessels, whereas only a positive trend was observed in isolated adipocytes ( Figure 5I and 5J).
Bioactive, Soluble TNF Is Shed by ADAM17 in Arteries of AT in Older Obese Patients
Next, we examined whether vascular endothelium-expressed ADAM17 itself is able to generate the soluble form of biologically active TNF. First, we directly measured soluble TNF in superfusates from freshly dissected AT arteries and found that the level of TNF was significantly elevated in AT artery superfusates in older obese patients ( Figure 6A ). To test whether TNF is bioactive, we performed a bioassay experiment in which AT artery was serially connected to a coronary arteriole, which served as a biosensor ( Figure 6B ). This setup permitted us to test the impact of soluble mediators produced by the upstream AT artery on endothelium-dependent dilation in the distal coronary arteriole. When the coronary arteriole was serially connected to the AT artery from an older obese patient, bradykinin-induced dilation in the coronary arteriole was significantly reduced compared with AT arteries from younger obese individuals ( Figure 6C ). The impaired coronary arteriole dilation imposed by aged-obese AT vessels was restored to level of young AT vessels by the ADAM17 inhibitor, TIMP3 (tissue inhibitor of metalloproteinase-3), PEGylated soluble TNF receptor, or by a TNF blocking antibody ( Figure 6D through  6F) . Selective removal of the endothelium from AT arteries also prevented the impaired distal coronary arteriole dilation imposed by AT vessels from older obese subjects ( Figure IV in the online-only Data Supplement). Moreover, when isolated coronary arterioles were exposed directly to TNF, dilation to bradykinin, but not to sodium nitroprusside, was significantly reduced ( Figure 6G and 6H). These data provide evidence that in AT, membrane-bound TNF in the vascular endothelium is efficiently cleaved by ADAM17 into a bioactive, soluble form, which is then able to impair coronary arteriole dilator function in older obese patients.
Diminished Interaction With Cav1 Augments ADAM17 Activity in Endothelial Cells
We next examined the mechanisms that underlie age-related increases in vascular ADAM17 activity. We measured protein expression of ADAM17 in AT arteries but found no significant differences between younger and older obese patients ( Figure 7A and 7B). Data from our mouse studies also suggest that the protein expression level of ADAM17 does not simply correlate with ADAM17 enzyme activity. Recent evidence indicates that Cav1 (the main structural protein of endothelial cell membrane caveolae) physically interacts with and regulates ADAM17 activity. 27, 29 The possible interaction between ADAM17 and Cav1 was also confirmed in this study by dual immunogold labeling of ADAM17 and Cav1 ( Figure 7C ). Interestingly, we found that the expression of Cav1 in AT arteries prominently declines with age ( Figure 7A ), and this corresponds with a significantly lower degree of colocalization of ADAM17 and Cav1 in AT arteries in older obese patients ( Figure 7D and 7E ).
In line with these human data, we found a significantly reduced expression of Cav1 in AT in aged HFD mice; however, we observed increased Cav1 expression in young HFD animals ( Figure 8A ). Along with our finding showing that aged mice exhibit a significantly elevated ADAM17 activity, we raised the possibility that Cav1 is a negative regulator of ADAM17 activity in AT. In support of this hypothesis, we found that the serum level of TNF ( Figure 8C ) and the activity of ADAM17 in AT ( Figure 8D ) are both significantly elevated in mice with genetic deletion of Cav1 when compared with that of wild-type mice. We found no significant changes in the protein expression of ADAM17 in AT ( Figure 8B ) and in the aorta in the Cav1 knockout mice ( Figure V in the online-only Data Supplement).
Moreover, we genetically silenced Cav1 and measured ADAM17 activity in cultured human coronary endothelial cells and also in primary isolated and cultured AT-derived vascular endothelial cells. We have found that depletion of Cav1 resulted in a significantly increased ADAM17 enzyme activity without affecting ADAM17 protein expression, in both human coronary endothelial cell and AT-derived endothelial cells ( Figure 8E through 8I) .
Discussion
The present study demonstrates that CMD is more prevalent in older patients who are obese. We identify prominent expression and increased biological activity of ADAM17 in the vascular endothelium of AT as a significant source of the excess soluble TNF production observed in these patients and a primary mechanism underlying impaired coronary arteriole dilation. We also found that the increased activity of ADAM17 arises from diminished inhibitory interactions with Cav1, owing to an agerelated decline in Cav1 expression. Collectively, our findings have important implications for proinflammatory changes in aged-obese AT, which contributes to the development of CMD and related cardiac complications in older, obese patients.
Cardiovascular complications arising from CMD frequently develop in the absence of occlusive atherosclerotic lesions or may occur after the successful reopening of the large occluded coronary arteries. 1 As such, CMD has recently been linked to HFpEF, which develops most often in older patients with various comorbidities, including obesity, hypertension, and type 2 diabetes mellitus but without compromised large coronary arteries. 3 In HFpEF, the underlying pathology seems to be driven by a chronic systemic inflammation state, 5, 6 but the pathological mediators of chronic inflammation and the underlying mechanisms of CMD remain poorly characterized. Obesity is considered one of the most potent risk factors for many cardiovascular diseases and is growing in prevalence in older adults at an alarming rate. 8 Our earlier studies showed that in mice and rats with HFD-induced obesity 32, 33 and also in obese patients, 34, 35 coronary arteriole dilator function is surprisingly preserved, in spite of significant adiposity and weight gain and elevated glucose and serum lipid levels. In the present study, we also found that younger obese patients, as well as younger HFD-fed obese mice, have maintained endothelium-dependent coronary arteriole dilations. Such maintained or even enhanced vasodilator capacity of coronary microvessels may imply vascular adaptations to hemodynamic and metabolic changes in the heart early on in obesity, a debated phenomenon, which is often implicated in obesity paradox. 36, 37 We 23 and others 24, 38 reported that aging of obese mice or rats, however, induces a prominent impairment in vasodilator function in mesenteric and skeletal muscle arteries. Similarly, in this study we found a significant age-related decline in human coronary arteriole dilator function in both obese men and women, but not in lean patients. These results were mirrored in mice, in which aging and obesity cooperatively induced impaired coronary artery dilations. Based on these observations, we reasoned that AT-specific mediator(s) may change and contribute to the development of aging-related deleterious vascular effects. A previous study by Bailey-Downs et al 24 indicated that higher levels of circulating, as well as AT-derived proinflammatory, cytokines coincide with age-related development of vascular dysfunction in obese mice. In the present study, we examined a direct, causative interrelationship between altered AT-derived inflammatory mediators and the development of CMD in aging and obesity. To this end, we performed AT transplantation across aged, aged obese, and young mice. 31 Importantly, we noted that coronary arteriole vasodilatory capacity in young recipients became significantly impaired after transplantation of aged obese, but not young or aged AT. We found that among the measured cytokines and inflammatory mediators TNF was markedly elevated in the young recipients of agedobese fat transplants, suggesting an important and selective role for TNF in the development of coronary arteriole dilator dysfunction.
AT, including the mediastinal fat pad, has been recognized as a significant source of the proinflammatory cytokine, TNF. 12, 21, 22, 39 Adipocytes and especially AT-infiltrated macrophages have been implicated as being the source of excess TNF, which promotes obesity-associated systemic complications, such as type 2 diabetes mellitus. 21, 40 Although our study Figure 6 . Bioactive, soluble tumor necrosis factor-α (TNF) is shed by ADAM17 in arteries of adipose tissue in older obese patients. Summary data of TNF concentrations in adipose tissue arteriole superfusates in younger (<69 y, n=4) and older (≥69 y, n=4) obese patients are shown, as measured by high-sensitivity multiplex ELISA (A). Images depict the design of a bioassay experiment, in which adipose tissue (AT) arteries (diameter: 100-250 µm) were directly connected to a biosensor artery (coronary arteriole [CA], diameter: ≈ 100 µm) with a small glass capillary (B). Connecting 2 CA with a glass capillary served as control. C, Diameter changes in the CA (biosensor) were measured in response to cumulative concentrations of endothelium-dependent agonist, bradykinin (BK, 10 -11 to 10 -7 mol/L) in younger (<69 y, n=6) and older (≥69 y, n=5) obese patients. In D-F, the CA (biosensor) was superfused by the AT artery and responses to BK were determined after selective treatment of the AT artery as indicated in the figure legends. BK and sodium nitroprusside (SNP)-induced dilations in CA were also obtained in the absence or presence of exposure to exogenous TNF (G and H). Data are shown as means±SEM. *P<0.05.
does not exclude the involvement of macrophages and adipocytes, we identify an important role of the vascular endothelium as a prominent source of soluble TNF in AT. It has been shown that vascular endothelial cells produce TNF in response to inflammatory stimulation by lipopolysaccharide or interleukin-1, in vitro. [41] [42] [43] Overexpression of TNF in cultured human umbilical vein endothelial cells results in the production of soluble TNF, which can be reduced by inhibition of TNF-converting enzyme, ADAM17. 41 The pathophysiological relevance of TNF production in the vascular endothelium and the regulated release of soluble TNF by ADAM17 have not yet been determined. In the present study, we have demonstrated for the first time that ADAM17 is functionally present in vascular endothelial cells in both rodent and human AT. We found that AT ADAM17 expression is induced by obesity and observed that ADAM17 becomes selectively activated in the aged AT. We also found that the release of soluble TNF by endothelial ADAM17 in AT arteries from older obese patients exhibited potent biological activity and was able to impair endothelium-dependent dilator function in remote coronary arterioles. In view of the elevated systemic and AT TNF levels in older obese patients, 21, 40, 44 it is likely that endothelial cells in AT contribute to systemic TNF levels. Unfortunately, serum samples were not available in our patient cohort, and this hypothesis can only be supported by our data from agedobese mice, including that of aged-obese AT transplantation experiments. Whether increased activity of ADAM17 in AT endothelium correlates with elevated serum TNF levels in older obese patients has yet to be determined. In this study, we further examined the potential mechanisms by which vascular endothelial ADAM17 becomes activated in the aged-obese AT. It has been shown that ADAM17 is expressed in mouse AT (both in visceral and in subcutaneous fat pads) and that mRNA expression level is increased in HFD-fed mice. 26 In this study, we found that both young and aged HFD mice had significantly increased protein expression of ADAM17 (young mice even higher), but only the aged mice exhibited a significantly increased ADAM17 enzyme activity, which was accompanied by elevated TNF levels in the serum of aged obese animals. Results from our human study showed that age-related increases in ADAM17 activity cannot be simply attributed to increased ADAM17 protein expression. Among other important regulatory mechanisms of ADAM17 activation, such as achieved by phosphorylation of the enzyme, 25 recent studies have shown that ADAM17 is localized within cell membrane caveolae, where its activity is regulated through caveolae compartmentalization and a direct interaction with Cav1, the main structural protein of membrane caveolae. [27] [28] [29] In the present study, we confirmed that ADAM17 is located in a close proximity of Cav1 in endothelium cell membrane in the AT. Of note that Cav1 expression in AT arteries was significantly reduced with age in the obese patients, and this was associated with a significantly lower degree of colocalization between Cav1 and ADAM17. Consistent with these observations, aging of mice was accompanied by a significantly reduced Cav1 levels in AT, which led to a significantly elevated ADAM17 enzyme activity. By contrast, young HFD mice had increased AT Cav1 and ADAM17 expression, which was however associated with only a modest increase in ADAM17 enzyme activity.
In line with our results, earlier in vitro studies have shown that Cav1 negatively regulates the enzyme activity of ADAM17 (ie, loss of Cav1 expression and diminished interaction increase ADAM17 activity) in cultured vascular smooth muscle cells 27 and neuronal cells. 29 In contrast, a study by D'Alessio et al 28 found that ADAM17 coimmunoprecipitates with Cav1, and its shedding activity is reduced after disruption of caveolae with methyl-β-cyclodextrin or by Cav1 silencing in human umbilical vein endothelial cells (EA.hy926). Similarly, a study by Takayanagi et al 45 showed that in Cav1 knockout mice angiotensin II-induced increase in ADAM17 expression and activity is diminished in the aortic vascular smooth muscle cells, which supports a positive regulatory role by Cav1 on ADAM17, in vivo. These studies indicated that Cav1 plays an important regulatory role by repressing or promoting ADAM17 enzyme activity and also highlighted the complexity and ambiguity of mechanisms through which Cav1 regulate ADAM17, both under normal and pathological conditions, in vitro and in vivo.
Our recent studies have shown that mice lacking Cav1 exhibit impaired NO-mediated coronary arteriole dilation 19 and that they are highly susceptible to the development of microvascular dysfunction and hypertension on commencing an HFD. 30 It is known that Cav1 plays an important role in the regulation and caveolae compartmentalization of endothelial NO synthase, 46 where endothelial NO synthase activity is inhibited by Cav1. [47] [48] [49] However, in Cav1 knockout mice lacking caveolae or under pathological conditions that are accompanied by disrupted endothelial caveolae function/structure, the activation of endothelial NO synthase becomes compromised and this may explain diminished NO-mediated dilation in coronary arterioles. 19 The nature of pathological mechanisms by which loss of Cav1/caveolae function directly or indirectly initiates coronary arteriole dysfunction remains incompletely understood. Interestingly, it has been shown that Cav1 knockout mice exhibit elevated TNF levels in the lung (even at baseline), which is further enhanced in response to bacteria-induced inflammatory stimuli. 50, 51 In the present study, we found that serum level of TNF is significantly elevated in Cav1 knockout mice, and thus, we have raised the possibility that increased ADAM17 activity may play a role in this process. In support of this, results from the present study show that AT in Cav1 knockout mice exhibit an increased ADAM17 activity. In addition, we found that genetic silencing of Cav1 in human AT-derived and also coronary artery endothelial cells lead to increased activity of ADAM17. These findings are in line with previous studies indicating an inhibitory effect by Cav1 on several vascular endothelial signaling pathways. 19, 30, 33, 52 Remarkably, recent studies revealed that impairments in Cav1-regulated fundamental homeostatic pathways are among the most important mediators of premature aging (reviewed in Zou et al 53 ). In this process, a diminished Cav1-mediated internalization and thus sustained activation of various plasma membrane-localized proteins/receptors promote cell senescence. 53 As such, an age-related decline in Cav1 expression and caveolae dysfunction would be a prime example, whereby aging enhances ADAM17 activation and promotes excess soluble TNF production, via a diminished Cav1-mediated ADAM17 internalization. Further studies are needed to examine the molecular base of interactions between ADAM17 and Cav1, Cav1-dependent ADAM17 internalization, and its impact on ADAM17 enzyme activity and soluble TNF production in more details.
There are several limitations in our study. Our human study was conducted in consecutive patients with heart diseases who underwent open heart surgery. This observational study was designed to determine the prevalence of CMD and also the impact of obesity and aging in this patient cohort. The majority (≈70%) of these patients also had large coronary artery disease and almost all patients had multiple comorbidities, including hypertension and diabetes mellitus. These comorbid conditions are highly prevalent in heart failure patients. Approximately 18% of these patients had heart failure and 5 had HFpEF diagnosis. Unfortunately, these limitations along with the limited number of HFpEF patients and the lack of follow up do not allow us to draw any firm conclusions on a mechanistic connection between CMD and the current or future incidence of HFpEF, especially in relation to increased ADAM17 activity and excess soluble TNF production by aged-obese AT. In addition, various biochemical measurements, such as ADAM17 protein expression and activity, as well as immunohistochemistry and immunoelectron microscopic assessment of ADAM17 tissue distribution were performed in a subset of consecutive patients, which patient cohort was overlapping with those with functional assessments of coronary arterioles, but may differ in the occurrence of comorbidities and medications. We did not have permission and did not collect blood from these patients who underwent heart surgery and therefore assessment of serum inflammatory mediators, such as TNF levels were not possible. Experiments in mouse models of aging, obesity, and AT transplantation were designed to overcome these and other limitations of our human study, which largely yielded supportive, complementary results regarding the role of obesity-and aging-induced proinflammatory changes in AT vascular endothelium. To provide further insights into the molecular mechanism through which vascular endothelium-expressed ADAM17 contributes to soluble TNF production by the aged and obese AT using transgenic mouse models may be considered in future studies. As such, endothelium-selective ADAM17 knockout mice were recently developed. 54 These transgenic mice show impaired collateral blood vessel growth, which indicates a pivotal role of endothelial ADAM17 in angiogenesis. It is known that adequate AT vascularization is critical for the maintenance of metabolism and function of the expanded AT, in which TNFmediated inflammatory mechanisms, likely through ADAM17 activation, play an important role. 55, 56 Therefore, a rather complex autocrine/paracrine (within the AT) and remote cardiovascular and other systemic effects of vascular endothelial ADAM17 activation and soluble TNF production can be envisioned in obesity and aging, which has yet to be investigated in future studies.
In conclusion, this study is the first to identify vascular endothelium-expressed ADAM17 in rodent and human AT as a significant source of bioactive, soluble TNF in obesity and aging. Our results indicate an important role for vascular endothelial ADAM17 in contributing to the excess production of TNF in older obese patients. Aging-related reduction in Cav1 expression and subsequently increased activity of endothelial ADAM17 may lead to excess TNF production. We propose that the augmented ADAM17/TNF signaling pathway in the vascular endothelium of AT acts remotely to promote coronary arteriole dysfunction and thereby contribute to the development of CMD and its related cardiac complications in older obese patients.
